Abstract
Genomic instability is one of the hallmarks of tumors that contributes to tumor heterogeneity and drug resistance. Genetically targeted cancer therapy that focused on genome instability has been a direction for tumor treatment of great interest. Synthetic lethality provides a new approach for the treatment of tumor suppressor gene especially DNA damage response pathway mutation-caused cancers that were not considered as a target in traditional genetic treatment previously. Here, we summarize the systematic classification of synthetic lethality and its mechanism which was divided into gene level, including cellular signaling pathway, cell cycle regulation, metabolism, and epigenetic regulation. The goal of this review was to help deepen the understanding of the mechanism of synthetic lethality and guide the direction for exploring the new synthetic lethal relationships.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.
References
Bailey, M. L., O’Neil, N. J., van Pel, D. M., Solomon, D. A., Waldman, T., & Hieter, P. (2014). Glioblastoma cells containing mutations in the cohesin component STAG2 are sensitive to PARP inhibition. Molecular Cancer Therapeutics, 13, 724–732. https://doi.org/10.1158/1535-7163.MCT-13-0749
Barnaba, N., & LaRocque, J. R. (2021). Targeting cell cycle regulation via the G2-M checkpoint for synthetic lethality in melanoma. Cell Cycle, 20, 1041–1051. https://doi.org/10.1080/15384101.2021.1922806
Behan, F. M., Iorio, F., Picco, G., Gonçalves, E., Beaver, C. M., Migliardi, G., Santos, R., Rao, Y., Sassi, F., Pinnelli, M., et al. (2019). Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature, 568, 511–516. https://doi.org/10.1038/s41586-019-1103-9
Bender, A., & Pringle, J. R. (1991). Use of a screen for synthetic lethal and multicopy suppressee mutants to identify two new genes involved in morphogenesis in Saccharomyces cerevisiae. Molecular and Cellular Biology, 11, 1295–1305. https://doi.org/10.1128/MCB.11.3.1295-1305.1991
Bian, Y., Kitagawa, R., Bansal, P. K., Fujii, Y., Stepanov, A., & Kitagawa, K. (2014). Synthetic genetic array screen identifies PP2A as a therapeutic target in Mad2-overexpressing tumors. Proceedings of the National Academy of Sciences, 111, 1628–1633. https://doi.org/10.1073/PNAS.1315588111
Bieging, K. T., Mello, S. S., & Attardi, L. D. (2014). Unravelling mechanisms of p53-mediated tumour suppression. Nature Reviews Cancer, 14, 359–370. https://doi.org/10.1038/NRC3711
Bitler, B. G., Aird, K. M., Garipov, A., Li, H., Amatangelo, M., Kossenkov, A. V., Schultz, D. C., Liu, Q., Shih, I. M., Conejo-Garcia, J. R., et al. (2015). Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers. Nature Medicine, 21, 231–238. https://doi.org/10.1038/nm.3799
Brown, J. S., O’Carrigan, B., Jackson, S. P., & Yap, T. A. (2017). Targeting DNA repair in cancer: Beyond PARP inhibitors. Cancer Discovery, 7, 20–37. https://doi.org/10.1158/2159-8290.CD-16-0860
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005). Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature, 434, 913–917. https://doi.org/10.1038/NATURE03443
Burkhart, D. L., & Sage, J. (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nature Reviews Cancer, 8, 671–682. https://doi.org/10.1038/NRC2399
Cao, R., & Zhang, Y. (2004). The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. Current Opinion in Genetics & Development, 14, 155–164. https://doi.org/10.1016/J.GDE.2004.02.001
Carrassa, L., Chilà, R., Lupi, M., Ricci, F., Celenza, C., Mazzoletti, M., Broggini, M., & Damia, G. (2012). Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo. Cell Cycle, 11, 2507–2517. https://doi.org/10.4161/CC.20899
Ceccaldi, R., Liu, J. C., Amunugama, R., Hajdu, I., Primack, B., Petalcorin, M. I. R., O’Connor, K. W., Konstantinopoulos, P. A., Elledge, S. J., Boulton, S. J., et al. (2015). Homologous-recombination-deficient tumours are dependent on Polθ-mediated repair. Nature, 518, 258–262. https://doi.org/10.1038/nature14184
Chabanon, R. M., Morel, D., Eychenne, T., Colmet-Daage, L., Bajrami, I., Dorvault, N., Garrido, M., Meisenberg, C., Lamb, A., Ngo, C., et al. (2021). PBRM1 deficiency confers synthetic lethality to DNA repair inhibitors in cancer. Cancer Research, 81, 2888–2902. https://doi.org/10.1158/0008-5472.CAN-21-0628
Chan, E. M., Tsukasa, S., McFarland, J. M., Gaeta, B., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., Liu, J. B., et al. (2016). WRN helicase is a synthetic lethal target in microsatellite unstable cancers Edmond. Physiology & Behavior, 176, 139–148. https://doi.org/10.1038/s41586-019-1102-x.WRN
Chan, N., Pires, I. M., Bencokova, Z., Coackley, C., Luoto, K. R., Bhogal, N., Lakshman, M., Gottipati, P., Oliver, F. J., Helleday, T., et al. (2010). Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Research, 70, 8045–8054. https://doi.org/10.1158/0008-5472.CAN-10-2352
Chung, C., Sweha, S. R., Pratt, D., Tamrazi, B., Panwalkar, P., Banda, A., Bayliss, J., Hawes, D., Yang, F., Lee, H. J., et al. (2020). Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell, 38, 334-349.e9. https://doi.org/10.1016/J.CCELL.2020.07.008
Couch, F. B., Bansbach, C. E., Driscoll, R., Luzwick, J. W., Glick, G. G., Bétous, R., Carroll, C. M., Jung, S. Y., Qin, J., Cimprich, K. A., et al. (2013). ATR phosphorylates SMARCAL1 to prevent replication fork collapse. Genes & Development, 27, 1610–1623. https://doi.org/10.1101/GAD.214080.113
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014). Drugging the undruggable RAS: Mission possible? Nature Reviews Drug Discovery, 13, 828–851. https://doi.org/10.1038/nrd4389
Davies, A. A., Masson, J. Y., McIlwraith, M. J., Stasiak, A. Z., Stasiak, A., Venkitaraman, A. R., & West, S. C. (2001). Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Molecular Cell, 7, 273–282. https://doi.org/10.1016/S1097-2765(01)00175-7
Duffy, S., Fam, H. K., Wang, Y. K., Styles, E. B., Kim, J. H., Ang, J. S., Singh, T., Larionov, V., Shah, S. P., Andrews, B., et al. (2016). Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer. Proceedings of the National Academy of Sciences, 113, 9967–9976. https://doi.org/10.1073/PNAS.1611839113
Emerling, B. M., Hurov, J. B., Poulogiannis, G., Tsukazawa, K. S., Choo-Wing, R., Wulf, G. M., Bell, E. L., Shim, H. S., Lamia, K. A., Rameh, L. E., et al. (2013). Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell, 155, 844. https://doi.org/10.1016/J.CELL.2013.09.057
Farmer, H., McCabe, H., Lord, C. J., Tutt, A. H. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921. https://doi.org/10.1038/NATURE03445
George, A., Kaye, S., & Banerjee, S. (2017). Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nature Reviews Clinical Oncology, 14, 284–296. https://doi.org/10.1038/nrclinonc.2016.191
Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L. C., Van Horn, R. D., Lin, X., Blosser, W., et al. (2019). Aurora A kinase inhibition is synthetic lethal with loss of the RB1 tumor suppressor gene. Cancer Discovery, 9, 248–263. https://doi.org/10.1158/2159-8290.CD-18-0469
Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144, 646–674. https://doi.org/10.1016/J.CELL.2011.02.013
Helleday, T. (2011). The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings. Molecular Oncology, 5, 387–393. https://doi.org/10.1016/j.molonc.2011.07.001
Hennessy, K. M., Lee, A., Chen, E., & Botstein, D. (1991). A group of interacting yeast DNA replication genes. Genes & Development, 5, 958–969. https://doi.org/10.1101/GAD.5.6.958
Hu, K., Li, K., Lv, J., Feng, J., Chen, J., Wu, H., Cheng, F., Jiang, W., Wang, J., Pei, H., et al. (2020). Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma. The Journal of Clinical Investigation, 130, 1752–1766. https://doi.org/10.1172/JCI124049
Hu, Y., & Guo, M. (2020). Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Science, 111, 3111–3121. https://doi.org/10.1111/CAS.14565
Huang, S., Pettaway, C. A., Uehara, H., Bucana, C. D., & Fidler, I. J. (2001). Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene, 20, 4188–4197. https://doi.org/10.1038/SJ.ONC.1204535
Jin, R., Yamashita, H., Yu, X., Wang, J., Franco, O. E., Wang, Y., Hayward, S. W., & Matusik, R. J. (2015). Inhibition of NF-kappa B signaling restores responsiveness of castrate-resistant prostate cancer cells to anti-androgen treatment by decreasing androgen receptor-variant expression. Oncogene, 34, 3700–3710. https://doi.org/10.1038/ONC.2014.302
Kaiser, C. A., & Schekman, R. (1990). Distinct sets of SEC genes govern transport vesicle formation and fusion early in the secretory pathway. Cell, 61, 723–733. https://doi.org/10.1016/0092-8674(90)90483-U
Kajino-Sakamoto, R., Fujishita, T., Taketo, M. M., & Aoki, M. (2021). Synthetic lethality between MyD88 loss and mutations in Wnt/β-catenin pathway in intestinal tumor epithelial cells. Oncogene, 40, 408–420. https://doi.org/10.1038/s41388-020-01541-3
Karin, M., & Greten, F. R. (2005). NF-kappaB: Linking inflammation and immunity to cancer development and progression. Nature Reviews Immunology, 5, 749–759. https://doi.org/10.1038/NRI1703
Kategaya, L., Perumal, S. K., Hager, J. H., & Belmont, L. D. (2019). Werner syndrome helicase is required for the survival of cancer cells with microsatellite instability. Iscience, 13, 488–497. https://doi.org/10.1016/J.ISCI.2019.02.006
Koh, S. B., Wallez, Y., Dunlop, C. R., de Quirós, B., Fernández, S., Bapiro, T. E., Richards, F. M., & Jodrell, D. I. (2018). Mechanistic distinctions between CHK1 and WEE1 inhibition guide the scheduling of triple therapy with gemcitabine. Cancer Research, 78, 3054–3066. https://doi.org/10.1158/0008-5472.CAN-17-3932
Koppula, P., Zhang, Y., Zhuang, L., & Gan, B. (2018). Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Communications, 38, 12. https://doi.org/10.1186/S40880-018-0288-x
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Oldreive, C., Petermann, E., Stewart, G., Brown, J., Lau, A., Pratt, G., et al. (2016). ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood, 127, 582–595. https://doi.org/10.1182/BLOOD-2015-05-644872
Kwok, M., Davies, N., Agathanggelou, A., Smith, E., Petermann, E., Yates, E., Brown, J., Lau, A., & Stankovic, T. (2015). Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway. Lancet (london, England), 385(Suppl 1), S58. https://doi.org/10.1016/S0140-6736(15)60373-7
Lissanu Deribe, Y., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R. A., Khor, T., Feng, N., et al. (2018). Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nature Medicine, 24, 1047–1057. https://doi.org/10.1038/S41591-018-0019-5
Lord, C. J., & Ashworth, A. (2017). PARP inhibitors: Synthetic lethality in the clinic. Science, 355(6330), 1152–1158.
Lucchesi, J. C. (1968). Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. Genetics, 59, 37–44.
Lv, J., Wang, J., Chang, S., Liu, M., & Pang, X. (2016). The greedy nature of mutant RAS: A boon for drug discovery targeting cancer metabolism? Acta Biochimica Et Biophysica Sinica (shanghai), 48, 17–26. https://doi.org/10.1093/ABBS/GMV102
Macheret, M., & Halazonetis, T. D. (2015). DNA replication stress as a hallmark of cancer. Annual Review of Pathology: Mechanisms of Disease, 10, 425–448. https://doi.org/10.1146/ANNUREV-PATHOL-012414-040424
Maiani, E., Milletti, G., Nazio, F., Holdgaard, S. G., Bartkova, J., Rizza, S., Cianfanelli, V., Lorente, M., Simoneschi, D., Di Marco, M., et al. (2021). AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. Nature, 592, 799–803. https://doi.org/10.1038/S41586-021-03422-5
Manning, A. L., & Dyson, N. J. (2012). RB: Mitotic implications of a tumour suppressor. Nature Reviews Cancer, 12, 220–226. https://doi.org/10.1038/NRC3216
McGowan, C. H., & Russell, P. (1993). Human Wee1 kinase inhibits cell division by phosphorylating p34cdc2 exclusively on Tyr15. EMBO Journal, 12, 75–85.
Mengwasser, K. E., Adeyemi, R. O., Leng, Y., Choi, M. Y., Clairmont, C., D’Andrea, A. D., & Elledge, S. J. (2019). Genetic screens reveal FEN1 and APEX2 as BRCA2 synthetic lethal targets. Molecular Cell, 73, 885. https://doi.org/10.1016/J.MOLCEL.2018.12.008
Meyer, S. N., Scuoppo, C., Vlasevska, S., Bal, E., Holmes, A. B., Holloman, M., Garcia-Ibanez, L., Nataraj, S., Duval, R., Vantrimpont, T., et al. (2019). Unique and shared epigenetic programs of the CREBBP and EP300 acetyltransferases in germinal center B cells reveal targetable dependencies in lymphoma. Immunity, 51, 535-547.e9. https://doi.org/10.1016/J.IMMUNI.2019.08.006
Millington, G. W. M. (2013). Mutations of the BRAF gene in human cancer, by Davies et al. (Nature 2002; 417: 949-54). Clinical and Experimental Dermatology, 38, 222–223. https://doi.org/10.1111/CED.12015
Morel, D., Almouzni, G., Soria, J. C., & Postel-Vinay, S. (2017). Targeting chromatin defects in selected solid tumors based on oncogene addiction, synthetic lethality and epigenetic antagonism. Annals of Oncology, 28, 254–269. https://doi.org/10.1093/ANNONC/MDW552
Muzny, D. M., Bainbridge, M. N., Chang, K., Dinh, H. H., Drummond, J. A., Fowler, G., Kovar, C. L., Lewis, L. R., Morgan, M. B., Newsham, I. F., et al. (2012). Comprehensive molecular characterization of human colon and rectal cancer. Nature, 487, 330–337. https://doi.org/10.1038/nature11252
Myers, S. H., Ortega, J. A., & Cavalli, A. (2020). Synthetic Lethality through the Lens of Medicinal Chemistry. Journal of Medicinal Chemistry, 63, 14151–14183. https://doi.org/10.1021/ACS.JMEDCHEM.0C00766
O’Neil, N. J., Bailey, M. L., & Hieter, P. (2017). Synthetic lethality and cancer. Nature Reviews Genetics, 18, 613–623. https://doi.org/10.1038/nrg.2017.47
Ogiwara, H., Sasaki, M., Mitachi, T., Oike, T., Higuchi, S., Tominaga, Y., & Kohno, T. (2016). Targeting p300 addiction in CBP-deficient cancers causes synthetic lethality by apoptotic cell death due to abrogation of MYC expression. Cancer Discovery, 6, 430–445. https://doi.org/10.1158/2159-8290.CD-15-0754
Ogiwara, H., Takahashi, K., Sasaki, M., Kuroda, T., Yoshida, H., Watanabe, R., Maruyama, A., Makinoshima, H., Chiwaki, F., Sasaki, H., et al. (2019). Targeting the vulnerability of glutathione metabolism in ARID1A-deficient cancers. Cancer Cell, 35, 177-190.e8. https://doi.org/10.1016/J.CCELL.2018.12.009
Pavlova, N. N., & Thompson, C. B. (2016). The emerging Hallmarks of cancer metabolism. Cell Metabolism, 23, 27–47. https://doi.org/10.1016/J.CMET.2015.12.006
Pilié, P. G., Tang, C., Mills, G. B., & Yap, T. A. (2019). State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews Clinical Oncology, 16, 81–104. https://doi.org/10.1038/S41571-018-0114-Z
Reaper, P. M., Griffiths, M. R., Long, J. M., Charrier, J. D., MacCormick, S., Charlton, P. A., Golec, J. M. C., & Pollard, J. R. (2011). Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature Chemical Biology, 7, 428–430. https://doi.org/10.1038/NCHEMBIO.573
Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377, 523–533. https://doi.org/10.1056/NEJMOA1706450
Russell, M. R., Levin, K., Rader, J., Belcastro, L., Li, Y., Martinez, D., Pawel, B., Shumway, S. D., Maris, J. M., & Cole, K. A. (2013). Combination therapy targeting the Chk1 and Wee1 kinases shows therapeutic efficacy in neuroblastoma. Cancer Research, 73, 776–784. https://doi.org/10.1158/0008-5472.CAN-12-2669
Ruzankina, Y., Schoppy, D. W., Asare, A., Clark, C. E., Vonderheide, R. H., & Brown, E. J. (2009). Tissue regenerative delays and synthetic lethality in adult mice after combined deletion of Atr and Trp53. Nature Genetics, 41, 1144–1149. https://doi.org/10.1038/NG.441
Sandhu, S. K., Schelman, W. R., Wilding, G., Moreno, V., Baird, R. D., Miranda, S., Hylands, L., Riisnaes, R., Forster, M., Omlin, A., et al. (2013). The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. The Lancet Oncology, 14, 882–892.
Sangster-Guity, N., Conrad, B. H., Papadopoulos, N., & Bunz, F. (2011). ATR mediates cisplatin resistance in a p53 genotype-specific manner. Oncogene, 30, 2526–2533. https://doi.org/10.1038/ONC.2010.624
Shen, J., Peng, Y., Wei, L., Zhang, W., Yang, L., Lan, L., Kapoor, P., Ju, Z., Mo, Q., Shih, I.-M., et al. (2015). ARID1A deficiency impairs the DNA damage checkpoint and sensitizes cells to PARP inhibitors. Cancer Discovery, 5, 752–767. https://doi.org/10.1158/2159-8290.CD-14-0849
Sherr, C. J., & McCormick, F. (2002). The RB and p53 pathways in cancer. Cancer Cell, 2, 103–112. https://doi.org/10.1016/S1535-6108(02)00102-2
Shiloh, Y., & Ziv, Y. (2013). The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nature Reviews Molecular Cell Biology, 14, 197–210. https://doi.org/10.1038/nrm3546
Takeda, K., Kaisho, T., & Akira, S. (2003). Toll-like receptors. Annual Review of Immunology, 21, 335–376. https://doi.org/10.1146/ANNUREV.IMMUNOL.21.120601.141126
Toledo, L. I., Altmeyer, M., Rask, M. B., Lukas, C., Larsen, D. H., Povlsen, L. K., Bekker-Jensen, S., Mailand, N., Bartek, J., & Lukas, J. (2013). ATR prohibits replication catastrophe by preventing global exhaustion of RPA. Cell, 155, 1088. https://doi.org/10.1016/J.CELL.2013.10.043
van Harten, A. M., Buijze, M., van der Mast, R., Rooimans, M. A., Martens-de Kemp, S. R., Bachas, C., Brink, A., Stigter-van Walsum, M., Wolthuis, R. M., & Brakenhoff, R. H. (2019). Targeting the cell cycle in head and neck cancer by Chk1 inhibition: A novel concept of bimodal cell death. Oncogenesis. https://doi.org/10.1038/S41389-019-0147-X
van Wietmarschen, N., Sridharan, S., Nathan, W. J., Tubbs, A., Chan, E. M., Callen, E., Wu, W., Belinky, F., Tripathi, V., Wong, N., et al. (2020). Repeat expansions confer WRN dependence in microsatellite-unstable cancers. Nature, 586, 292–298. https://doi.org/10.1038/S41586-020-2769-8
Varshney, D., Spiegel, J., Zyner, K., Tannahill, D., & Balasubramanian, S. (2020). The regulation and functions of DNA and RNA G-quadruplexes. Nature Reviews Molecular Cell Biology, 21, 459. https://doi.org/10.1038/S41580-020-0236-X
Walker, G. J., Flores, J. F., Glendening, J. M., Lin, A., Markl, I. D., & Fountain, J. W. (1998). Virtually 100% of melanoma cell lines harbor alterations at the DNA level within CDKN2A, CDKN2B, or one of their downstream targets. Genes, Chromosomes & Cancer, 22, 157–163. https://doi.org/10.1002/(sici)1098-2264(199806)22:2%3c157::aid-gcc11%3e3.0.co;2-n
Wang, K., Kan, J., Yuen, S. T., Shi, S. T., Chu, K. M., Law, S., Chan, T. L., Kan, Z., Chan, A. S., Tsui, W. Y., et al. (2011). Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature Genetics, 43, 1219–1223. https://doi.org/10.1038/NG.982
Wang, T., Yu, H., Hughes, N. W., Liu, B., Kendirli, A., Klein, K., Chen, W. W., Lander, E. S., & Sabatini, D. M. (2017). Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell, 168, 890-903.e15. https://doi.org/10.1016/J.CELL.2017.01.013
Weber, A. M., Bokobza, S. M., Devery, A. M., & Ryan, A. J. (2013). Abstract B91: Combined ATM and ATR kinase inhibition selectively kills p53-mutated non-small cell lung cancer (NSCLC) cells. Molecular Cancer Therapeutics, 12, B91–B91. https://doi.org/10.1158/1535-7163.TARG-13-B91
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010). arid1a mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine, 363, 1532–1543. https://doi.org/10.1056/nejmoa1008433
Williamson, C. T., Miller, R., Pemberton, H. N., Jones, S. E., Campbell, J., Konde, A., Badham, N., Rafiq, R., Brough, R., Gulati, A., et al. (2016). ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. Nature Communication, 7, 1–13. https://doi.org/10.1038/ncomms13837
Wright, S., & Dobzhansky, T. (1946). Genetics of natural populations; experimental reproduction of some of the changes caused by natural selection in certain populations of Drosophila pseudoobscura. Genetics, 31, 125–156.
Wu, C., Lyu, J., Yang, E. J., Liu, Y., Zhang, B., & Shim, J. S. (2018). Targeting AURKA-CDC25C axis to induce synthetic lethality in ARID1A-deficient colorectal cancer cells. Nature Communications. https://doi.org/10.1038/s41467-018-05694-4
Xu, H., Di Antonio, M., McKinney, S., Mathew, V., Ho, B., O’Neil, N. J., Santos, N. D., Silvester, J., Wei, V., Garcia, J., et al. (2017). CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours. Nature Communications. https://doi.org/10.1038/NCOMMS14432
Yamada, L., Saito, M., Thar Min, A. K., Saito, K., Ashizawa, M., Kase, K., Nakajima, S., Onozawa, H., Okayama, H., Endo, H., et al. (2021). Selective sensitivity of EZH2 inhibitors based on synthetic lethality in ARID1A-deficient gastric cancer. Gastric Cancer, 24, 60–71. https://doi.org/10.1007/S10120-020-01094-0
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009). IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine, 360, 765–773. https://doi.org/10.1056/NEJMOA0808710
Yu, D., Liu, Y., Zhou, Y., Ruiz-Rodado, V., Larion, M., Xu, G., & Yang, C. (2020). Triptolide suppresses IDH1-mutated malignancy via Nrf2-driven glutathione metabolism. Proceedings of the National Academy of Sciences, 117, 9964–9972. https://doi.org/10.1073/PNAS.1913633117
Zeman, M. K., & Cimprich, K. A. (2014). Causes and consequences of replication stress. Nature Cell Biology, 16, 2–9. https://doi.org/10.1038/NCB2897
Zhao, D., Cai, L., Lu, X., Liang, X., Li, J., Chen, P., Ittmann, M., Shang, X., Jiang, S., Li, H., et al. (2020). Chromatin regulator CHD1 remodels the immunosuppressive tumor microenvironment in PTEN-deficient prostate cancer. Cancer Discovery, 10, 1374–1387. https://doi.org/10.1158/2159-8290.CD-19-1352
Zhao, D., Lu, X., Wang, G., Lan, Z., Liao, W., Li, J., Liang, X., Chen, J. R., Shah, S., Shang, X., et al. (2017). Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature, 542, 484–488. https://doi.org/10.1038/NATURE21357
Funding
This study was supported by grants from the National Natural Science Foundation of China (82172820, 81771332); the Fundamental Research for the Central University, the Natural Science Foundation of Shanghai (22ZR1466200, 22ZR1451200).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Pang, Y., Cheng, M., Chen, M. et al. Synthetic lethality in personalized cancer therapy. GENOME INSTAB. DIS. 4, 121–135 (2023). https://doi.org/10.1007/s42764-022-00080-3
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s42764-022-00080-3